HDECO: A method for Decreasing energy and cost by using virtual machine migration by considering hybrid parameters by Arash GhorbanniaDelavar (22563696)

“…<h2>Summary</h2><p dir="ltr">This research introduces <b>HDECO</b> (Hybrid Decreasing Energy and Cost Optimization) — a method designed to reduce both energy consumption and execution cost in cloud datacenters through intelligent virtual machine migration. …”

ActAs and CoT prompt strategies do not result in decreased error rate for tasks with increasing complexity. by Jacqueline A. Jansen (14894276)

Self-correction prompt strategy results in decreased error rate for all tasks with increasing complexity. by Jacqueline A. Jansen (14894276)

fileCont prompt strategy results in decreased error rate for some tasks with increasing complexity. by Jacqueline A. Jansen (14894276)

Displacement cloud maps. by Maogang Tian (21485116)

Subjects:

Point cloud fusion instance effect. by Hongliang Zou (20707270)

Subjects:

Schematic diagram of time stamp synchronization between LIDAR and camera in a multi-sensor system. by Hongliang Zou (20707270)

Subjects:

The number of COVID-19 patients admitted to the health system during the pandemic with the timing of data collection for the 2 study phases. by Elie Mulhem (22537863)

Subjects:

GPT-4 results in decreased error rate for all tasks with increasing complexity when compared to GPT-3.5-turbo. by Jacqueline A. Jansen (14894276)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Thematic clouds for lectures. by Ignacio García-Espona (21395335)

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. …”

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: